Literature DB >> 24525660

Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: a 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.

Hong Jin Jeon1, Jong-Min Woo, Seung-Hwan Lee, Eui-Joong Kim, Seockhoon Chung, Jee Hyun Ha, Maurizio Fava, David Mischoulon, Ji-Hae Kim, Jung-Yoon Heo, Bum-Hee Yu.   

Abstract

Although many patients with major depressive disorder (MDD) complain of neurocognitive impairment, the effects of antidepressant medications on neurocognitive functions remain unclear. This study compares neurocognitive effects of tianeptine and escitalopram in MDD. Patients with MDD (N = 164) were randomly assigned in a 1:1 ratio to either tianeptine (37.5 mg/d) or escitalopram (10 mg/d) for 12 weeks. Outcome measures included clinical improvement, subjective cognitive impairment on memory and concentration, the Mini-Mental State Examination, the Continuous Performance Test, the Verbal Learning Test, and the Raven Progressive Matrices, assessed every 4 weeks. After 12 weeks, the tianeptine group showed significant improvement in commission errors (P = 0.002), verbal immediate memory (P < 0.0001), Mini-Mental State Examination (P < 0.0001), delayed memory (P < 0.0001), and reasoning ability (P = 0.0010), whereas the escitalopram group improved in delayed memory and reasoning ability but not in the other measures. Both groups significantly improved in subjective cognitive impairment in memory (P < 0.0001) and concentration (P < 0.0001). Mixed effects model repeated measures analyses revealed that the tianeptine group had a significant improvement in scores of commission errors (F = 6.64, P = 0.011) and verbal immediate memory (F = 4.39, P = 0.038) from baseline to 12 weeks, compared with the escitalopram group, after controlling for age, sex, education years, baseline scores, and changes of depression severity. The treatment of MDD with tianeptine led to more improvements in neurocognitive functions, especially in commission errors and verbal immediate memory, compared with escitalopram, after controlling for changes in depression severity. Both drugs improved subjective cognitive impairment of memory and concentration.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24525660     DOI: 10.1097/JCP.0000000000000072

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  3 in total

1.  Modulation of atypical brain activation during executive functioning in autism: a pharmacological MRI study of tianeptine.

Authors:  Robert H Wichers; James L Findon; Auke Jelsma; Vincent Giampietro; Vladimira Stoencheva; Dene M Robertson; Clodagh M Murphy; Sarah Blainey; Grainne McAlonan; Christine Ecker; Katya Rubia; Declan G M Murphy; Eileen M Daly
Journal:  Mol Autism       Date:  2021-02-19       Impact factor: 7.509

2.  Effects of Tianeptine Treatment on Depression and Cognitive Function in Patients with Alzheimer's Disease: A 12-Month Retrospective Observational Study.

Authors:  José María García-Alberca; Esther Gris; Paz de la Guía; Silvia Mendoza
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

3.  Baseline predictors of cognitive change in the treatment of major depressive episode: systematic review.

Authors:  Zoe A Barczyk; Katie M Douglas; Richard J Porter
Journal:  BJPsych Open       Date:  2020-10-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.